Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Rating Increased to Sell at ValuEngine
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.
A number of other brokerages also recently weighed in on INO. Stifel Nicolaus reiterated a “buy” rating and set a $11.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday, May 25th. Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 8th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, June 9th. Aegis raised their target price on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. Finally, Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research note on Tuesday, July 11th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Inovio Pharmaceuticals has a consensus rating of “Buy” and an average price target of $20.78.
Inovio Pharmaceuticals (NASDAQ INO) opened at 5.49 on Friday. The company’s market capitalization is $414.00 million. The firm’s 50-day moving average price is $6.88 and its 200 day moving average price is $6.81. Inovio Pharmaceuticals has a 12-month low of $5.32 and a 12-month high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The firm had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. During the same period last year, the business posted ($0.26) EPS. The business’s revenue was up 229.2% compared to the same quarter last year. On average, analysts expect that Inovio Pharmaceuticals will post ($0.93) earnings per share for the current year.
In related news, Director David B. Weiner sold 8,000 shares of the firm’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 10.60% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after buying an additional 226,861 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $1,411,000. Credit Suisse AG boosted its position in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 69,068 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock valued at $3,708,000 after buying an additional 62,045 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $392,000. 22.92% of the stock is currently owned by institutional investors and hedge funds.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.